BR0313494A - Métodos de administração e realce da absorção de agentes farmacêuticos - Google Patents
Métodos de administração e realce da absorção de agentes farmacêuticosInfo
- Publication number
- BR0313494A BR0313494A BR0313494-6A BR0313494A BR0313494A BR 0313494 A BR0313494 A BR 0313494A BR 0313494 A BR0313494 A BR 0313494A BR 0313494 A BR0313494 A BR 0313494A
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- enhancement
- administration
- absorption
- pharmaceutical agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
"METODOS DE ADMINISTRAçãO E REALCE DA ABSORçãO DE AGENTES FARMACêUTICOS". Composições farmacêuticas compreendendo um agente farmacêutico macromolecular na forma micelar misturada são divulgadas. As micelas misturadas são formadas de um sulfato de alquila de metal de álcali, e pelo menos três compostos de formação de micela diferentes como descrito no relatório descritivo. O tamanho das micelas variam entre cerca de 1 e 10 nanómetros. Os métodos para a administração das composições são também divulgados. Um método preferido para a administração da presente composição é através da região bucal da boca, o qual tenha sido demonstrado alcançar os nìveis pico de plasma do agente farmacêutico em cerca de trinta minutos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/222,240 US7087215B2 (en) | 1998-12-21 | 2002-08-16 | Methods of administering and enhancing absorption of pharmaceutical agents |
PCT/IB2003/003908 WO2004016243A2 (en) | 2002-08-16 | 2003-08-14 | Methods of administering and enhancing absorption of pharmaceutical agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0313494A true BR0313494A (pt) | 2005-07-05 |
Family
ID=31886615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0313494-6A BR0313494A (pt) | 2002-08-16 | 2003-08-14 | Métodos de administração e realce da absorção de agentes farmacêuticos |
Country Status (8)
Country | Link |
---|---|
US (1) | US7087215B2 (pt) |
EP (1) | EP1556003A2 (pt) |
JP (1) | JP2006501220A (pt) |
BR (1) | BR0313494A (pt) |
CA (1) | CA2494132C (pt) |
EC (1) | ECSP055604A (pt) |
MX (1) | MXPA05001887A (pt) |
WO (1) | WO2004016243A2 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003528701A (ja) * | 2000-04-03 | 2003-09-30 | バテル メモリアル インスティチュート | 定量吐出装置および液体配合物 |
AU3664102A (en) * | 2000-12-01 | 2002-06-11 | Battelle Memorial Institute | Method for stabilizing biomolecules in liquid formulations |
WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
TW200621794A (en) * | 2004-10-06 | 2006-07-01 | Akzo Nobel Nv | Pulmonary administration of an antithrombotic compound |
AP2008004447A0 (en) * | 2005-11-30 | 2008-04-30 | Generex Pharm Inc | Orally absorbed pharmaceutical formulation and method of administration |
DK1976521T3 (en) * | 2006-01-25 | 2015-04-27 | Insys Therapeutics Inc | Sublingual fentanyl spray |
US20080085331A1 (en) * | 2006-10-06 | 2008-04-10 | Gluskin Anna E | Composition and method for raising blood glucose level |
GB0621707D0 (en) * | 2006-10-31 | 2006-12-13 | Univ London Pharmacy | Formulations for delivery via pressurised metered dose inhalers |
CA2698749C (en) | 2007-08-02 | 2017-05-23 | Insys Therapeutics Inc. | Sublingual fentanyl spray |
US20090263476A1 (en) * | 2008-04-16 | 2009-10-22 | Jobdevairakkam Christopher N | Composition of Rapid Disintegrating Direct Compression Buccal Tablet |
EP2504019A2 (en) | 2009-11-25 | 2012-10-03 | ArisGen SA | Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion |
EP3708190A1 (en) | 2010-02-26 | 2020-09-16 | Novo Nordisk A/S | Stable antibody containing compositions |
US20130136733A1 (en) | 2010-05-28 | 2013-05-30 | Novo Nordisk A/S | Stable Multi-Dose Compositions Comprising an Antibody and a Preservative |
GB2483579A (en) * | 2010-06-30 | 2012-03-14 | Londonpharma Ltd | Sublingual formulations comprising methadone and ethanol for use in reducing pain |
US8580853B2 (en) | 2011-06-13 | 2013-11-12 | Howard PHYKITT | Analgesic composition and method of making the same |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53107408A (en) | 1977-02-28 | 1978-09-19 | Yamanouchi Pharmaceut Co Ltd | Micellar preparation for rectal infusion |
US4900730A (en) | 1981-01-14 | 1990-02-13 | Toyo Jozo Co., Ltd. | Preparation which promotes the absorption of peptides |
NL193099C (nl) | 1981-10-30 | 1998-11-03 | Novo Industri As | Gestabiliseerde insuline-oplossing. |
GB8332556D0 (en) | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
EP0158441B2 (en) | 1984-03-08 | 2001-04-04 | Phares Pharmaceutical Research N.V. | Liposome-forming composition |
GB8430346D0 (en) | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
CA1274774A (en) | 1985-04-15 | 1990-10-02 | Kenneth S. Su | Method for administering insulin |
DK179286D0 (da) | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | Insulinpraeparat |
US4673679A (en) | 1986-05-14 | 1987-06-16 | E. I. Du Pont De Nemours And Company | Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration |
NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
US5174988A (en) | 1989-07-27 | 1992-12-29 | Scientific Development & Research, Inc. | Phospholipid delivery system |
CA2033725C (en) | 1990-01-24 | 2001-05-29 | Folker Pittrof | Pharmaceutical and cosmetic compositions containing a salt of cholanic acid |
GB9007052D0 (en) | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
DE69122464T2 (de) | 1990-03-30 | 1997-02-20 | Yasunori Morimoto | Transdermal absorbierbares mittel mit morphin hydrochlorid |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5292499A (en) | 1990-09-11 | 1994-03-08 | University Of Wales College Of Cardiff | Method of preparing medical aerosol formulations including drug dissolved in reverse micelles |
US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
IT1255449B (it) | 1992-06-30 | 1995-10-31 | Fabio Berlati | Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci. |
US5981591A (en) | 1992-12-04 | 1999-11-09 | Mayor Pharmaceutical Laboratories, Inc. | Sprayable analgesic composition and method of use |
WO1994021228A1 (en) | 1993-03-17 | 1994-09-29 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing a diol-diacid derived dispersing aid |
WO1994021229A1 (en) | 1993-03-17 | 1994-09-29 | Minnesota Mining And Manufacturing Company | Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid |
US5492688A (en) | 1993-04-28 | 1996-02-20 | The Center For Innovative Technology | Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent |
US5747445A (en) | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
KR100419037B1 (ko) * | 1994-03-07 | 2004-06-12 | 넥타르 테라퓨틱스 | 폐를통한인슐린의전달방법및그조성물 |
US5451408A (en) | 1994-03-23 | 1995-09-19 | Liposome Pain Management, Ltd. | Pain management with liposome-encapsulated analgesic drugs |
US6524557B1 (en) * | 1994-12-22 | 2003-02-25 | Astrazeneca Ab | Aerosol formulations of peptides and proteins |
JP2740153B2 (ja) | 1995-03-07 | 1998-04-15 | エフ・ホフマン−ラ ロシユ アーゲー | 混合ミセル |
US5653987A (en) | 1995-05-16 | 1997-08-05 | Modi; Pankaj | Liquid formulations for proteinic pharmaceuticals |
WO1996040057A2 (en) | 1995-06-07 | 1996-12-19 | Alliance Pharmaceutical Corp. | Reverse fluorocarbon emulsion compositions for drug delivery |
ATE288255T1 (de) | 1996-04-12 | 2005-02-15 | Novadel Pharma Inc | Polares bukkales spray |
US5891465A (en) | 1996-05-14 | 1999-04-06 | Biozone Laboratories, Inc. | Delivery of biologically active material in a liposomal formulation for administration into the mouth |
US6255502B1 (en) | 1996-07-11 | 2001-07-03 | Farmarc Nederland B.V. | Pharmaceutical composition containing acid addition salt of basic drug |
US6214375B1 (en) | 1996-07-16 | 2001-04-10 | Generex Pharmaceuticals, Inc. | Phospholipid formulations |
US6090407A (en) | 1997-09-23 | 2000-07-18 | Research Development Foundation | Small particle liposome aerosols for delivery of anti-cancer drugs |
IL122084A (en) | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
US6221378B1 (en) | 1998-02-10 | 2001-04-24 | Generex Pharmaceuticals Incorporated | Mixed micellar delivery system and method of preparation |
US6017545A (en) | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
US6193997B1 (en) | 1998-09-27 | 2001-02-27 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using membrane mimetics |
US6290987B1 (en) | 1998-09-27 | 2001-09-18 | Generex Pharmaceuticals, Inc. | Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids |
US6261539B1 (en) | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
US6375975B1 (en) | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
US6294153B1 (en) | 1998-12-21 | 2001-09-25 | Generex Pharmaceuticals, Inc. | Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
US6451286B1 (en) | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
US6312665B1 (en) | 1998-12-21 | 2001-11-06 | Generex Pharmaceuticals Incorporated | Aerosol formulations for buccal and pulmonary application |
US6436367B1 (en) | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
US6271200B1 (en) | 1998-12-21 | 2001-08-07 | Generex Pharmaceuticals Inc. | Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles |
AU2879100A (en) | 1999-02-12 | 2000-08-29 | Miles A. Libbey Iii | Formulation and system for intra-oral delivery of pharmaceutical agents |
CA2364610C (en) | 1999-03-19 | 2006-12-19 | Generex Pharmaceuticals Inc. | Pharmaceutical solubilized in aerosol propellant |
CA2375914A1 (en) * | 1999-06-04 | 2000-12-14 | Delrx Pharmaceutical Corporation | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
US6225343B1 (en) | 1999-06-16 | 2001-05-01 | Nastech Pharmaceutical Company, Inc. | Compositions and methods comprising morphine gluconate |
US6432383B1 (en) * | 2000-03-30 | 2002-08-13 | Generex Pharmaceuticals Incorporated | Method for administering insulin |
EP1392262A1 (en) * | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
-
2002
- 2002-08-16 US US10/222,240 patent/US7087215B2/en not_active Expired - Lifetime
-
2003
- 2003-08-14 EP EP03787979A patent/EP1556003A2/en active Pending
- 2003-08-14 CA CA2494132A patent/CA2494132C/en not_active Expired - Fee Related
- 2003-08-14 WO PCT/IB2003/003908 patent/WO2004016243A2/en not_active Application Discontinuation
- 2003-08-14 MX MXPA05001887A patent/MXPA05001887A/es unknown
- 2003-08-14 JP JP2004528775A patent/JP2006501220A/ja not_active Withdrawn
- 2003-08-14 BR BR0313494-6A patent/BR0313494A/pt not_active Application Discontinuation
-
2005
- 2005-02-16 EC EC2005005604A patent/ECSP055604A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2004016243A2 (en) | 2004-02-26 |
CA2494132C (en) | 2015-01-20 |
EP1556003A2 (en) | 2005-07-27 |
US7087215B2 (en) | 2006-08-08 |
WO2004016243A3 (en) | 2004-05-21 |
MXPA05001887A (es) | 2005-06-17 |
ECSP055604A (es) | 2005-04-18 |
US20030157029A1 (en) | 2003-08-21 |
CA2494132A1 (en) | 2004-02-26 |
JP2006501220A (ja) | 2006-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0313494A (pt) | Métodos de administração e realce da absorção de agentes farmacêuticos | |
MXPA02011436A (es) | Composiciones farmaceuticas micelares para aplicacion bucal y pulmonar. | |
DE60134535D1 (de) | Micelläre arzneimittel zur bukkalen und pulmonaren anwendung | |
BR0313451A (pt) | Composições farmacêuticas para liberação bucal de medicações de alìvio de dor | |
BR0012488A (pt) | Composição farmacêutica, métodos para melhorar a taxa de absorção de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para melhorar o inìcio do benefìcio terapêutico de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para inibição de gastroirritação em um mamìfero, e para tratamento de mamìferos necessitando do tratamento proporcionado por um ou mais do que um agente farmaceuticamente ativo, e, processo para preparar uma composição farmacêutica | |
SG146648A1 (en) | Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation | |
BR0007781A (pt) | Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf | |
EE05533B1 (et) | Farmatseutiline kompositsioon ja preparaat, mis sisaldab mikroniseeritud drospirenooni ja strogeeni ning nende kasutamine | |
AU2002225772A1 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
BR9909915A (pt) | Composições adjuvantes | |
RU2010148556A (ru) | Композиции, содержащие хлорид олова | |
ES2187300A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos. | |
EA200400357A1 (ru) | Дезинтегрирующиеся в ротовой полости композиции валдекоксиба | |
TW200509907A (en) | Indol-6-yl sulfonamide derivatives, their preparation and their use in medicaments | |
CA2396927A1 (en) | Stabilized ascorbic acid solutions; use thereof; process for their obtention; and formulations comprising the same | |
BR0008509A (pt) | Composição farmacêutica oral estabilizada contendo iodeto e iodato e método | |
BR0012696A (pt) | Composição oftálmica | |
BRPI0417672A (pt) | processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas | |
JP4970805B2 (ja) | 皮膚外用剤 | |
CA2175494A1 (en) | Microparticular Pharmaceutical Compositions | |
BR0014979A (pt) | Composição hormonal e sua utilização | |
NO20003674L (no) | Faste, farmasøytiske preparater inneholdende miltefosin for oral administrering ved behandling av Leishmaniase | |
BRPI0407660A (pt) | composição de lipossoma para redução de ativação de complemento induzida por lipossoma | |
JP7359909B2 (ja) | 口腔用組成物の製造方法、口腔用組成物の口腔内塗布部との密着性を向上させる方法および口腔用組成物の口腔内塗布部における滞留性を向上させる方法。 | |
BR9801985A (pt) | Composição cremosa aplicada na terapeutica da doença de peyronie. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |